Medtech industry faces reshaping as tariffs, inflation, and geopolitical tensions accelerate supply chain disruptions

Rising tariffs, inflation, and geopolitical tensions are forcing the medical technology sector to re-evaluate production and distribution models, particularly for diabetes devices, amid increasing industry resilience efforts.

GlobalData Healthcare says tariffs, inflation and shifting geopolitical tensions are placing fresh strain on medical technology supply chains, with diabetes devices now part of a wider industry reckoning over where products are made, how they move and what patients ultimately pay. The company is set to explore those pressures in a webinar on 18 August, when analysts Andrew Thompson and Charlie Whelan will examine how global manufacturing networks and pricing structures are being reshaped by macroeconomic forces.

The discussion comes as medtech companies across the sector are trying to reduce exposure to trade disruption and rising costs. PwC has said the broader pharmaceutical and medtech supply chain is being forced to adapt through digital tools, advanced analytics, redundancy and a mix of onshoring and nearshoring. Trade specialists at Baker McKenzie have similarly argued that tariffs, export controls and sanctions are pushing companies to reassess their global footprints more quickly than before.

For diabetes technology, the issue is especially sensitive because production is often spread across multiple countries, which can leave manufacturers vulnerable to tariff shocks and inflationary pressure at several points in the chain. The webinar is expected to look at revenue and volume patterns in the market and at the link between gate prices and wider economic conditions, with a focus on what those shifts mean for manufacturers, payers and patients.

The pressure on the sector is already visible in company responses. MedTech Dive reported that GE HealthCare expects a smaller tariff hit in 2026 after moving parts of its supply chain and shifting products into more tariff-efficient locations. That kind of repositioning reflects a broader industry trend: as trade rules tighten and geopolitical risk rises, medtech groups are increasingly weighing whether resilience matters more than the lowest possible production cost.